Suspire1 - Eosinophilic COPD

  • Study Sponsor and Protocol Number: 
    Areteia AR-DEX-23-05
  • Specialty:
    Pulmonology
  • Type:
    Investigational Drug
  • Inclusion:
    Age 40-80
    COPD diagnosis for at least 2 years prior to enrollment
    At least 1 moderate to severe COPD exacerbation in the last 2 years
    ICS/LABA/LAMA dual or triple therapy for at least 12 weeks prior to enrollment
  • Exclusion:
    Asthma
    Pneumonia in the last 4 weeks

    •